These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection]. Hunyady B; Kovács B; Battyáni Z Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373 [TBL] [Abstract][Full Text] [Related]
4. Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. Pearlman BL Lancet Infect Dis; 2012 Sep; 12(9):717-28. PubMed ID: 22647717 [TBL] [Abstract][Full Text] [Related]
5. Review of boceprevir and telaprevir for the treatment of chronic hepatitis C. Wilby KJ; Partovi N; Ford JA; Greanya E; Yoshida EM Can J Gastroenterol; 2012 Apr; 26(4):205-10. PubMed ID: 22506260 [TBL] [Abstract][Full Text] [Related]
6. [Current indications for triple therapy in hepatitis C virus infection]. Molina Pérez E; Fernández Castroagudín J; Domínguez Muñoz E Gastroenterol Hepatol; 2012 Apr; 35(4):266-77. PubMed ID: 22410706 [TBL] [Abstract][Full Text] [Related]
7. Very short course of triple therapy including telaprevir for chronic hepatitis C: a possible strategy in selected patients. Corti G; Salomoni E; Baragli F Int J Infect Dis; 2014 Feb; 19():85-6. PubMed ID: 24246771 [TBL] [Abstract][Full Text] [Related]
8. Response-guided therapy in patients with genotype 1 hepatitis C virus: current status and future prospects. Lawitz EJ; Membreno FE J Gastroenterol Hepatol; 2014 Aug; 29(8):1574-81. PubMed ID: 24852401 [TBL] [Abstract][Full Text] [Related]
9. Anemia management in patients with chronic viral hepatitis C. Hynicka LM; Heil EL Ann Pharmacother; 2013 Feb; 47(2):228-36. PubMed ID: 23386076 [TBL] [Abstract][Full Text] [Related]
10. Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase? Pascale A; Serfaty L J Hepatol; 2013 Feb; 58(2):391-4. PubMed ID: 23063419 [TBL] [Abstract][Full Text] [Related]
11. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J; J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346 [TBL] [Abstract][Full Text] [Related]
12. Telaprevir (Incivek) and boceprevir (Victrelis) for chronic hepatitis C. Med Lett Drugs Ther; 2011 Jul; 53(1369):57-9. PubMed ID: 21778964 [No Abstract] [Full Text] [Related]
13. Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials. Sitole M; Silva M; Spooner L; Comee MK; Malloy M Clin Ther; 2013 Feb; 35(2):190-7. PubMed ID: 23369368 [TBL] [Abstract][Full Text] [Related]
14. New treatments for chronic hepatitis C virus infection. Corouge M; Pol S Med Mal Infect; 2011 Nov; 41(11):579-87. PubMed ID: 21764234 [TBL] [Abstract][Full Text] [Related]
15. Telaprevir for the treatment of chronic hepatitis C infection. Muir AJ Expert Rev Anti Infect Ther; 2011 Dec; 9(12):1105-14. PubMed ID: 22114960 [TBL] [Abstract][Full Text] [Related]
16. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Ramachandran P; Fraser A; Agarwal K; Austin A; Brown A; Foster GR; Fox R; Hayes PC; Leen C; Mills PR; Mutimer DJ; Ryder SD; Dillon JF Aliment Pharmacol Ther; 2012 Mar; 35(6):647-62. PubMed ID: 22296568 [TBL] [Abstract][Full Text] [Related]
17. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir. Chen EY; Sclair SN; Czul F; Apica B; Dubin P; Martin P; Lee WM Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1014-20.e1-2. PubMed ID: 23602817 [TBL] [Abstract][Full Text] [Related]
18. Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response. Vierling JM; Davis M; Flamm S; Gordon SC; Lawitz E; Yoshida EM; Galati J; Luketic V; McCone J; Jacobson I; Marcellin P; Muir AJ; Poordad F; Pedicone LD; Albrecht J; Brass C; Howe AY; Colvard LY; Helmond FA; Deng W; Treitel M; Wahl J; Bronowicki JP J Hepatol; 2014 Apr; 60(4):748-56. PubMed ID: 24362076 [TBL] [Abstract][Full Text] [Related]
20. Seizures in patients with chronic hepatitis C treated with NS3/4A protease inhibitors: does pharmacological interaction play a role? Milazzo L; Falvella FS; Magni C; Gervasoni C; Peri AM; Cattaneo D; Antinori S; Vidale S Pharmacology; 2013; 92(5-6):235-7. PubMed ID: 24192929 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]